Gene Therapy and Exudative Age Related Macular Degeneration

Tracy Doll, OD

COPE #20591-PS

Expires December 1, 2010

1 credits, $39

Section: Retina and Posterior Segment

Introduction:

Age Related Macular Degeneration (ARMD) is the leading cause of blindness in Industrialized Nations[1]. Currently 1.8 million Americans over the age of 40 are affected with advanced age related macular degeneration. This number is projected to grow to 2.9 million by the year 2020[2].

Prevent Blindness America released a report this April estimating the cost of adult related vision related disorders (including age-related macular degeneration, cataract, diabetic retinopathy, primary open-angle glaucoma, refractive error, visual impairment and blindness) at $51.4 billion. An estimated $575 million is spent solely on ARMD costs[3].

New potential methods of ARMD treatment and management are currently being researched in hopes to lessen the impact ARMD has on our society.

 

Figure 3

 

TAKE THIS COURSE

 

View this course as a PDF